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AbstrACt
background: Coronary perforation is currently a rare, but 
potentially catastrophic complication. The aim of the study 
was to evaluate the incidence, predictors, management and 
prognosis of coronary perforations at a hospital with a large 
number of percutaneous coronary interventions (PCIs). Methods: 
Clinical, angiographic, procedural and in-hospital outcomes of 
patients with or without coronary perforations were compared. 
Univariate analysis was performed to determine the predic-
tors of this complication. results: From December 2007 to 
January 2012, 5,585 consecutive patients were submitted to 
PCI and 18 had coronary perforation (0.32%), of whom 55.5% 
were female and 38.9% were diabetic. In this group, the left 
anterior descending artery was the most frequently treated 
vessel (61.1%) as well as type C lesion (61.1%) and chronic 
occlusions were approached in 27.8% of these cases. Most 
of the coronary perforations (11/18) had a lower complexity 
according to the modified Ellis classification, whereas the 
remaining perforations were classified as grades III (6/18) or 
IV (1/18). The balloon-catheter device was responsible for 
perforation in 61.1% of the cases. Prolonged inflation with 
a balloon-catheter and heparin reversal with protamine was 
performed in 72.2% and 88.9% of the cases, respectively. 
Only 1 patient (5.6%) required an emergency surgery due 
to cardiac tamponade. There were no deaths associated with 
coronary perforation. According to the univariate analysis, 
coronary perforation predictors were: female gender (P = 
0.03), chronic obstructive pulmonary disease (P = 0.006) and 
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resuMo
Incidência, Manejo e Prognóstico  
de Perfurações Coronárias
Introdução: A perfuração coronária na atualidade é complica-
ção rara, mas potencialmente catastrófica. Nosso objetivo foi 
avaliar a incidência, os preditores, o manejo e o prognóstico 
das perfurações coronárias na experiência de um serviço de 
cardiologia intervencionista com grande volume de interven-
ções coronárias percutâneas (ICPs). Métodos: Comparamos 
as características clínicas, angiográficas e do procedimento 
e a evolução intra-hospitalar de pacientes que apresentaram 
ou não perfuração coronária. Análise univariada foi realizada 
para determinar os preditores dessa complicação. resultados: 
No período de dezembro de 2007 a janeiro de 2012, 5.585 
pacientes consecutivos foram submetidos a ICP e 18 apresen-
taram perfuração coronária (0,32%), dos quais 55,5% eram do 
sexo feminino e 38,9% eram diabéticos. Nesse grupo, a artéria 
descendente anterior foi o vaso mais frequentemente tratado 
(61,1%), assim como a lesão do tipo C (61,1%), e as oclusões 
crônicas foram abordadas em 27,8% desses casos. A maioria das 
perfurações coronárias (11/18) apresentou menor complexidade 
de acordo com a classificação de Ellis modificada, enquanto as 
demais foram qualificadas como graus III (6/18) ou IV (1/18). 
O cateter-balão foi o dispositivo responsável pela perfuração 
em 61,1% dos casos. Realizou-se insuflação prolongada com 
cateter-balão e inativação da heparina com protamina em 72,2% 
e 88,9% dos casos, respectivamente. Apenas 1 paciente (5,6%) 
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chronic occlusion (P < 0.01). Conclusions: In our experience, 
coronary perforation was a rare event, which was managed 
conservatively in most of the cases and was associated with 
a good in-hospital outcome.
 
 
 
DesCrIPtors: Coronary artery disease. Coronary stenosis. 
Coronary angiography. Angioplasty.
necessitou de abordagem cirúrgica de emergência em decor-
rência de tamponamento cardíaco. Não houve óbito associado 
à perfuração coronária. Na análise univariada, os preditores de 
perfuração coronária foram: sexo feminino (P = 0,03), doença 
pulmonar obstrutiva crônica (P = 0,006) e oclusão crônica 
(P < 0,01). Conclusões: Em nossa experiência, a perfuração coro-
nária foi evento raro, controlada conservadoramente na maioria 
dos casos e com evolução hospitalar satisfatória.
DesCrItores: Doença da artéria coronariana. Estenose co-
ronária. Angiografia coronária. Angioplastia.
C oronary perforation is a rare complication of the percutaneous coronary intervention (PCI) procedure that is characterised by a rupture of the arterial 
lumen, resulting in the leakage of its contents. This 
complication can be caused by several percutaneous 
devices used during PCI, such as guidewires, athero-
tomes (directional or rotational), balloon catheters, and 
metallic stents.1 Even with the large increase in the 
number of PCIs around the world, coronary perforation 
currently remains an infrequent phenomenon, albeit 
a potentially catastrophic event that may lead to the 
occurrence of acute myocardial infarction (AMI), cardiac 
tamponade, emergency surgery and death. In general, 
coronary perforation occurs in 0.1% to 0.6% of coro-
nary angioplasty procedures, and its occurrence has 
historically been associated with PCIs in lesions with 
complex morphology, including calcification and severe 
chronic occlusion, the use of atherectomy devices and 
hydrophilic guidewires.2–12 Moreover, previous studies 
have reported mortality due to coronary perforation in 
approximately 5% to 10% of cases, with advanced age, 
type (or severity) of perforation, and the occurrence of 
cardiac tamponade requiring emergency surgery as the 
commonly reported predictors.3,4
When treating coronary perforation, it is necessary 
to institute immediate therapy aimed at containing the 
coronary leak and decompression of the pericardial 
cavity. Such measures include, but are not limited to, 
inactivation of antithrombin agents, prolonged insuffla-
tion with a balloon catheter, coated stent implantation, 
coil embolisation, pericardiocentesis or even emergency 
heart surgery.3,4
This study aimed to report the incidence, manage-
ment, prognosis and predictors of coronary perfora-
tion occurring in patients undergoing PCI in the daily 
practice of an interventional cardiology service with a 
high number of PCIs.
Methods
study design and population
A retrospective analysis of data from patients treated 
at the Department of Invasive Cardiology of the Instituto 
Dante Pazzanese de Cardiologia (São Paulo, SP, Brazil) 
from December of 2007 to January of 2012 was perfor-
med. During this period, all patients undergoing elective 
or emergency PCI had their information related to clini-
cal, angiographic and procedural characteristics and the 
in-hospital clinical evolution prospectively collected and 
stored in a dedicated electronic database following a 
pre-established protocol. We identified patients who 
had coronary perforation during PCI. Patients who had 
coronary perforation during PCI were identified, and then 
compared to patients who did not suffer this complication.
Coronary perforation classification and 
definitions
The coronary perforations followed the modified 
Ellis classification:2
– Type I: extraluminal crater with no linear contrast 
extravasation that suggests dissection (Figure 1A);
Figure 1 – In A, the left circumflex artery with an extraluminal crater (type I 
Ellis perforation). In B, the left circumflex artery with contrast extrava-
sation into the pericardium with an orifice < 1 mm diameter (type II 
Ellis perforation). In C, left anterior descending artery showing rupture 
in its middle third, with diameter > 1 mm and significant extravasa-
tion of contrast outside the arterial lumen (type III Ellis perforation). 
In D, rupture of an important septal branch (left anterior descending 
artery branch) showing extravasation of contrast to the septum, with no 
extravasation of contrast to the pericardium (type IV Ellis perforation).
A
C
B
D
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– Type II: myocardial or pericardial blushing with 
an orifice < 1 mm (Figure 1B);
– Type III: frank contrast medium extravasation into 
the pericardium through an orifice > 1 mm in diameter 
(Figure 1C) and
– Type IV: perforation with contrast extravasation 
directly into the left ventricle, to the coronary sinus 
or other vascular chamber, excluding the pericardium 
(Figure 1D).
Cardiac tamponade was defined by the presence of 
one or more of the following characteristics: a) systemic 
hypotension (systolic blood pressure < 90 mmHg), with 
evidence of paradoxical pulse by clinical assessment 
or invasive method; b) evidence of pericardial effusion 
by angiography; and c) echocardiographic evidence 
of significant respiratory variation of the transmitral 
Doppler velocity, dilated inferior vena cava with collapse 
during inspiration, and/or diastolic collapse of the right 
ventricular free wall.13 Periprocedural AMI was defined 
by the elevation of the biomarker creatine kinase MB 
fraction > three times the upper limit of normal values 
on examination performed up to 24 hours after the 
procedure. Major adverse clinical events (MACE) were 
defined by the combined outcomes of death from any 
cause, AMI, and emergency heart surgery. Angiographic 
success was defined by the following criteria: a) obtai ning 
flow a Thrombolysis In Myocardial Infarction (TIMI) grade 
of 3; b) the absence of thrombus, dissection, or perfora-
tion with active contrast extravasation; and c) residual 
stenosis < 30% (quantitative coronary angiography) in the 
treated segment after the procedure. Procedural success 
was defined as angiographic success plus the absence 
of MACE during the index hospitalisation.
Procedure
The PCI procedures were performed according 
to current guidelines, aimed at optimal angiographic 
results after coronary device implantation.14 The route 
of arterial access, the choice of material to perform 
the PCI (guidewire, balloon catheter, etc.), the type 
of stent used, the stent implantation technique, and 
the adjunctive medical therapy were at the discretion 
of the surgeon. Regarding antithrombotic therapy, the 
pretreatment included acetylsalicylic acid at a dose of 
100 mg/day in cases of chronic use (> seven days) or 
200 mg given > 24 hours before PCI and clopidogrel at 
a loading dose of 300 mg > 24 hours before surgery or 
600 mg before the procedure (preferably > two hours) 
in patients with acute coronary syndrome. After the 
procedure, patients were instructed to maintain dual 
antiplatelet therapy (acetylsalicylic acid 100 mg plus 
clopidogrel 75 mg) for at least one month in case of 
bare-metal stent implantation and one year for drug-
eluting stents. As for antithrombin therapy adminis-
tered during the procedure, heparin was administered 
intravenously at a dose of 70 U/kg to 100 U/kg body 
weight to maintain an activated clotting time > 250 
seconds or > 200 seconds in cases of concomitant 
administration of glycoprotein IIb/IIIa inhibitors, at the 
discretion of the surgeon.
Complementary examinations were conducted 
according to the institution protocol and included 
12-lead ECG before, immediately after, and daily after 
the procedure until hospital discharge. The labora-
tory tests included cardiac biomarkers pre-procedure, 
in the first 24 hours after the procedure, and daily 
until discharge.
Angiographic analysis
Qualitative and quantitative angiographic analyses 
were performed before and after the procedure. A qualita-
tive assessment was performed according to the criteria 
used for the classification of the American College of 
Cardiology and the American Heart Association (ACC/
AHA),15 where lesions were considered type C when 
at least one of the following was present: a) length 
> 20 mm (diffuse lesion), b) significant tortuosity (three 
or more angles ≥ 75 degrees in the segment proximal 
to the lesion), c) significant angulation of the lesion 
(≥ 90 degrees), d) bifurcated lesion with an incapacity 
to protect the side branch with the guidewire, e) lesion 
in degenerate saphenous vein and f) chronic occlusion 
(≥ three months). The analysis of quantitative coronary 
angiography was performed offline by professio nals who 
had experience with the method, through a validated and 
commercially available program (QAngio XA – version 
7.3 – Medis Medical Imaging Systems bv – Leiden, the 
Netherlands). Lesion extension was delimited by the 
distance between points immediately before and after the 
target stenosis considered free of atheromatous disease, 
that is, the transition between the stenotic segment and 
the normal references. The minimal lumen diameter 
(MLD) and the reference diameter (RD) were used to 
calculate the diameter stenosis (DS) through the following 
formula: DS (%) = [1 − (MLD/RD)] x 100. Immediate 
gain was defined as the pre-and post-procedure MLD 
difference (post-procedure MLD – pre-procedural MLD). 
The balloon:artery ratio was determined by the maxi-
mum diameter of the inflated catheter-balloon divided 
by the RD. Quantitative varia bles were reported for 
intrastent segment and intrasegment, which incorporate 
the intrastent segment plus the 5-mm borders in the 
persistent regions, according to previously described 
methodology.
statistical analysis
Qualitative variables were expressed as absolute 
frequencies and percentages and compared by chi-squared 
test or Fisher's exact test, as appropriate. Quantitative 
variables were expressed as the mean and standard 
deviation and compared using Student’s t-test. A value 
of P < 0.05 was considered significant.
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Results
PCIs were performed in 5,585 patients, of whom 
18 (0.32%) had coronary perforation; 55.5% were 
females, with a mean age of 62.8 ± 13.3 years, and 
38.9% were diabetics (Table 1). The group of coronary 
perforation patients had a higher prevalence of females 
(P = 0.03) and history of chronic obstructive pulmonary 
disease (P = 0.006).
The pre-procedural angiographic data are shown in 
Table 2. In the group of patients with coronary perforation, 
the left anterior descending artery was the most frequently 
treated vessel (61.1%). The chronic occlusions were more 
frequently treated (27.8% vs. 4.5%; P < 0.01), but the 
prevalence of lesions with moderate /severe calcifications 
(50% vs. 43.1%; P = 0.56), lesions > 20 mm (38.9% vs. 
26%; P = 0.21), C-type morphology (61.1% vs. 51%; 
P = 0.40), and vessels ≤ 2.5 mm (44.4% vs. 42.3%; 
P = 0.85) did not differ between groups.
During the procedure, a balloon catheter device was 
the cause of coronary perforation in 61.1% (11/18) of cases, 
including, two ruptures during the pre-dilation, two during 
stenting, and seven while conducting post-dilation (Table 
3). In the remainder (7/18), a guidewire was responsible 
for coronary perforation, with a hydrophilic guidewire 
accounting for 22.2% (4/18) of cases and a non-hydrophilic 
guidewire accounting for 16.7% (3/18) of cases.
Simple perforations (type I) occurred in 33.3% (6/18) 
of patients, and their management included expectant 
and/or conservative treatment in four of six cases. Type 
II coronary perforations (27.8%, 5/18) were associated 
with guidewires (n = 2) or balloon-catheter dilation 
(n = 3). In these cases, the treatment included the admi-
nistration of protamine for heparin inactivation associated 
with prolonged balloon inflation, and there was in-hospital 
periprocedural AMI in two cases. The type III coronary 
perforations were more often associated with ruptures 
caused by balloon catheters (50%), and one case had 
cardiac tamponade, requiring emergency surgery. Figure 
2 shows the case with pericardial extravasation treated 
by prolonged inflation. Type IV perforation occurred in 
one patient post-dilation. There were no deaths associa ted 
with coronary perforation in any of the 18 cases, and 
the success rate of the procedure was 77.8% (n = 14), 
tAbLe 1 
baseline clinical characteristics
Variable
With coronary perforation
n = 18
No coronary perforation
n = 5567 P
Age, years 62.8 ± 13.3 60.9 ± 11.8 0.58
Female gender, n (%) 10 (55.5) 1,733 (31.1) 0.03
Diabetes mellitus, n (%) 7 (38.9) 1,876 (33.7) 0.64
Insulin use 1 (5.6) 194 (3.5) 0.63
Systemic arterial hypertension, n (%) 16 (88.9) 4,757 (85.5) 0.68
Dyslipidaemia, n (%) 12 (66.7) 3,726 (66.9) 0.98
History of smoking, n (%) 11 (61.1) 2,718 (48.8) 0.30
Current smoking 3 (16.7) 1,073 (19.3) 0.78
Family history of CAD, n (%) 2 (11.1) 672 (12.1) 0.90
AMI > 30 days, n (%) 7 (38.9) 2,258 (40.6) 0.86
Previous PCI, n (%) 4 (22.2) 745 (13.4) 0.28
Previous CABG, n (%) 1 (5.6) 225 (4) 0.75
Previous stroke, n (%) 1 (5.6) 113 (2) 0.31
History of COPD, n (%) 2 (11.1) 86 (1.5) 0.006
Renal failure, n (%) 7 (38.9) 1,551 (27.9) 0.30
Clinical picture, n (%) 0.70
Silent ischemia 2 (11.1) 640 (11.5)
Stable angina 10 (55.5) 2,555 (45.9)
Acute coronary syndrome 6 (33.3) 2,366 (42.5)
CAD = coronary artery disease; COPD = chronic obstructive pulmonary disease; AMI = acute myocardial infarction; PCI = percutaneous 
coronary intervention; n = number of patients; CABG = coronary artery bypass graft surgery.
Silva et al. 
Coronary Perforations
Rev Bras Cardiol Invasiva. 
2012;20(3):295-302
299
tAbLe 2 
Angiographic characteristics
Variable 
With coronary perforation
(n = 18)
No coronary perforation  
(n = 5,567 patients/ 
6,753 lesions) P
Number of lesions per patient 1 ± 0 1.2 ± 0.1 < 0.01
Target-vessel, n (%) 0.38
LAD 11 (61.1) 3,208 (47.5)
LCx 5 (27.8) 1,918 (928.4)
RCA 2 (11.1) 1,628 (24.1)
Lesion location, n (%) 0.96
Ostial/proximal 8 (44.4) 3,167 (46.9)
Medial 8 (44.4) 2,978 (44.1)
Distal 2 (11.1) 608 (9)
Moderate or severe calcification, n (%) 9 (50) 2,911 (43.1) 0.56
Type C lesion, n (%) 5 (27.8) 304 (4.5) < 0.01
Chronic occlusion, n (%) 11 (61.1) 3,444 (51) 0.40
Lesions > 20 mm, n (%) 7 (38.9) 1,754 (26) 0.21
Vessels < 2.5 mm, n (%) 8 (44.4) 2,856 (42.3) 0.85
RCA = right coronary artery; LCx = left circumflex artery; LAD = left = anterior descending artery.
tAbLe 3 
types of perforation-related devices, management and prognosis of patients  
with coronary perforation (n = 18)
type of coronary perforation*
type I
(n = 6)
type II
(n = 5)
type III
(n = 6)
type IV
(n = 1) n (%)
Device responsible for the perforation
Non-hydrophilic guidewire 1 1 1 0 3 (16.7)
Hydrophilic guidewire 2 1 1 0 4 (22.2)
Pre-dilation balloon 1 1 0 0 2 (11.1)
Post-dilation balloon 1 2 3 1 7 (38.9)
Stent (during implantation) 1 0 1 0 2 (11.1)
Clinical management
Expectant conduct 2 0 0 0 2 (11.1)
UFH reversal with protamine 4 5 6 1 16 (88.9)
Prolonged insufflation of coronary balloon 2 5 5 1 13 (72.2)
Pericardiocentesis 0 0 1 0 1 (5.6)
Emergency surgery 0 0 1 0 1 (5.6)
In-hospital prognosis
Death 0 0 0 0 0
Cardiac tamponade 0 0 1 0 1 (5.6)
Periprocedural AMI 0 2 3 1 6 (33.3)
Hospital discharge 6 5 6 1 18 (100)
*Modified Ellis classification.
UFH = unfractionated heparin; AMI = acute myocardial infarction; n = number of patients.
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as there was failed attempted occlusion recanalisation 
in three cases and suboptimal angiographic results (re-
sidual stenosis > 30%) in one case. The median length 
of hospitalisation was 3.1 days (range 2–58 days), and 
one patient who underwent emergency surgery presented 
a number of postoperative complications, including renal 
failure, requiring hemodialysis.
Table 4 shows the results of the quantitative coro-
nary angiography analysis in patients with coronary 
perforation. The balloon-artery ratio was 1.2 ± 0.1, as 
determined when measuring the maximum balloon dia-
meter during inflation resulting in coronary perforation.
disCussion
The main findings of the current study, which included 
a retrospective analysis of a large cohort of patients 
(n = 5,585) undergoing PCI in the daily practice of a 
tertiary public hospital were: a) coronary perforation was 
a rare phenomenon (0.32%), with an incidence similar 
to that reported in the literature (0.1%–0.6%);2–12 b) most 
of the perforations were caused by balloon-catheter di-
lation; c) the clinical management was successfull and 
included a conservative approach in cases of simple 
coronary perforation and invasive approach in cases of 
marked extraluminal contrast extravasation; and d) in 
the univariate analysis, the predictors included female 
gender, history of chronic obstructive pulmonary disease 
and chronic occlusion.
Coronary perforations have different presentations 
and are classically classified into types I-III or, more 
recently, types I-IV (modified Ellis classification) according 
to the degree and direction of contrast extravasation.3 It 
is noteworthy that the incidence of subsequent compli-
cations varies according to the perforation severity. For 
types I, II and III-IV, the rates of adverse events were 
as follows: AMI, 0% to 29%, 13% to 29%, and 0% 
to 30%, respectively; cardiac tamponade, 6% to 8%, 
5% to 13%, and 20% to 63%, respectively; emergency 
surgery, 15% to 24%, 0% to 24%, and 50% to 60%, 
respectively, and death, 0% to 6%, 0% to 6%, and 
19% to 21%, respectively.3,4,11
The same trend was observed in the present study 
in relation to AMI (0%, 40%, 43%), cardiac tamponade 
(0%, 0%, 14%) and emergency surgery (0%, 0%, 14%) 
for coronary perforations types I, II and III-IV, respectively; 
however, there were no fatal cases associated with this 
complication. This finding may be associated with the low 
incidence and the resulting small sample included in the 
present series. Regarding the devices that cause coronary 
perforation, previous studies suggest that guidewires (mainly 
the hydrophilic type) are the most often responsible for 
coronary perforations types I and II. However, types III 
and IV occur, in general, due to balloon-catheters or 
atheroablative devices.7 It is interesting to note that of the 
11 cases of coronary perforation types I and II observed 
in the present analysis, 46% (n = 5) were caused by 
guidewires (hydrophilic and non-hydrophilic), and the 
remainder were caused by balloon-catheters.
Regarding the clinical and angiographic predictors, 
a significant association was observed in the univariate 
analysis between the occurrence of coronary perfora-
tion and female gender, history of chronic obstructive 
pulmonary disease, and chronic occlusion. Hendry 
et al.16 demonstrated that female gender, advanced 
age, coronary calcification, use of a cutting balloon 
and rotational atherectomy, and treatment of chronic 
occlusion were predictors of coronary perforation; howe ver, 
coronary perforation was not associated with the use of 
high-inflation pressures in balloons, suggesting the safety 
Figure 2 – In A, arterial lumen rupture with diameter > 1 mm and 
contrast extravasation through an orifice (type III Ellis perforation). Note 
the position of the balloon catheter in place to achieve prolonged 
inflation. In B, the balloon catheter inflated at the site of perforation 
and positioning of a pigtail catheter into the pericardial cavity after 
performing the pericardiocentesis.
A B
tAbLe 4 
Quantitative coronary angiography cases  
with coronary perforation
Variable n = 18
Pre-procedural
Lesion extension, mm 20.8 ± 6.1
RD, mm 3.05 ± 0.65
MLD, mm 0.56 ± 0.48
%DS 82.5 ± 13.2
Post-procedural
RD, mm 3.3 ± 0.6
Intra-segment
MLD, mm 2.39 ± 0.44
% DS 24.4 ± 26.9
Immediate gain, mm 1.64 ± 0.67
Intrastent
MLD, mm 2.62 ± 0.45
%DS 13.2 ± 7.1
Immediate gain, mm 1.94 ± 0.57
MLD = minimal luminal diameter; RD = reference diameter; 
DS = diameter stenosis; n = number of patients.
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of such a practice, which aims to provide an optimal 
angiographic result with adequate stent expansion, 
which could, theoretically, minimize late complications 
such as restenosis and stent thrombosis. In general, it 
is recommended that a balloon:artery ratio between 
1 and 1.1 is used for optimal stent implantation, 
with an angiographic result goal of residual stenosis 
< 30%.14 However, the feasibility of this procedure 
is often limited based on the degree of rigidity and 
resistance of the atherosclerotic plaque, especially in 
calcified lesions. Thus, suboptimal results often lead to 
the use of balloon-catheters of greater calibre, which 
can be inflated at very high pressures to optimize 
stent expansion. Consequently, such procedure may 
lead to coronary rupture. In the present study, half the 
patients had moderate or severe lesion calcification 
and the mean balloon:artery ratio of cases of coronary 
perforation caused by balloon-catheters (either pre– or 
post-dilatation or during stent implantation) was 1.2 
(greater than that recommended in clinical practice).
Moreover, the studies by Fasseas et al.17 and by 
Gruberg et al.4 identified the use of atheroablative de-
vices and female gender in coronary perforation. In the 
multivariate analysis of Shimony et al.,18 the treatment of 
total chronic occlusion was the strongest independent 
predictor of coronary perforation; the other independent 
variables included were lesion calcification and AMI. 
Regarding female gender, previous studies suggest that 
body surface area, and not gender, was the determi-
ning factor of the association commonly found between 
females and coronary perforation, as women have, on 
average, lower weight and smaller body surface area 
when compared to men.19 It is noteworthy that the 
small-calibre coronary vessels have been systematically 
identified as an important predictor of PCI failure, 
including acute complications, such as coronary perfora-
tion, as well as late complications, such as restenosis 
and stent thrombosis.18 In the present analysis, 44% of 
patients with coronary perforation had small vessels (< 
2.5 mm); however, the difference was not significant.
Regarding the management and treatment of coro-
nary perforations, several authors have demonstrated 
that most types I and II Ellis perforations can be treated 
conservatively with inactivation of unfractionated heparin 
with protamine (suggested dose: 1 mg per 100 units 
of unfractionated heparin), prolonged inflation with a 
balloon-catheter, and the use of coils and coated stents. 
Type III and IV perforations may have more severe 
complications, often requiring more invasive measures 
such as surgery and emergency pericardiocentesis.4,16–18,20 
In the present series with 18 patients, only one patient 
with type III coronary perforation required such proce-
dures. In general, the present population had a high-
risk profile, either due to their clinical characteristics 
or the lesion complexity, as shown in Tables 1 and 2. 
However, the incidence of coronary perforation is in 
agreement with the literature.2–12 When this complication 
occurs, it must be treated immediately, with reversal of 
unfractionated heparin with protamine and prolonged 
inflation of a balloon-catheter for a minimum period 
between 15 and 30 minutes, using control injections to 
confirm that extravasation of contrast medium through 
the arterial lumen has stopped. In addition, it is recom-
mended that a further transthoracic echocardiogram in 
the catheterisation laboratory is performed, and seriate 
echocardiography should be performed in the intensive 
care unit, due to the possibility of the later formation 
of massive pericardial effusion, which may cause future 
hemodynamic damage. Pericardiocentesis or emergency 
surgery is reserved for cases with cardiac tamponade 
and/or significant hemodynamic damage. Nonetheless, 
specific cases may require individual approaches; the 
surgeon’s experience and service infrastructure are 
extremely important. Embolisation with coils or coated 
stents is an alternative approach; however, logistical and 
availability issues may hinder its routine use.
ConClusions
In daily practice complex patients, the incidence 
of coronary perforation was rare and was significantly 
associated with the female gender, history of chronic 
obstructive pulmonary disease and chronic occlusion 
coronary lesions. These patients were successfully treated 
through conservative conduct (without pericardiocentesis 
and/or emergency surgery) in most cases, with satisfac-
tory in-hospital outcomes.
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